China Public Payer Lowers Expectations As Record Novel Drugs Gain Approvals
Executive Summary
Cost concerns and an increased number of potential entrants will dominate the annual adjustments to China's the national reimbursement drug list, with regulators moving to manage companies' expectations.
You may also be interested in...
HutchMed CEO On Novel Drug Pricing Strategy In China
A successful IPO on the Hong Kong Stock Exchange will jump-start the company’s R&D and new drug approvals, says HutchMed's CEO in an interview.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Explained: How China’s Public Payer Wants To Define Innovative Drugs
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter revealed during a recent industry event. The disclosure has unnerved pharma companies, which have been hit by sharp drug price discounts that were required by the public payer in exchange for reimbursement coverage.